Janus Henderson Investors

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in

Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesForesite CapitalFrazier Life SciencesOrbiMed+6 more

Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.

AI & Machine LearningBiotechSouth San Francisco, US

Jason Coloma(Chief Executive Officer)in

Co-investorsAndreessen HorowitzARCH Venture PartnersForesite CapitalFrazier Life SciencesGV (Google Ventures)Venrock Healthcare Capital Partners

Monopar Therapeutics is a clinical-stage biotechnology company developing radiopharmaceuticals for oncology imaging and treatment of advanced solid tumors, along with ALXN1840, a late-stage investigational treatment for Wilson Disease, a rare genetic disorder.

BiotechHealthtechMedical DevicesLake Forest, US

Chandler D. Robinson(Executive Officer, Director, Promoter)inChristopher M. Starr(Executive Officer, Director)Andrew P. Mazar(Executive Officer, Director)

BoardMichael J. Brown(Director)

Co-investorsRA Capital

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.

AI & Machine LearningBiotechDeep TechMedical Devices

Mathai Mammen(CEO, President and Chairman)in

Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystNextech Invest+5 more

Pasithea is a biotechnology company focused on the discovery and development of therapeutics for central nervous system disorders and RASopathies.

BiotechDeep TechHealthtechVenice, US

Lawrence Steinman(Director)Tiago Reis Marques(Director)inIsrael Maxx Abramowitz(Executive Officer, Director)Craig Auringer(Executive Officer, Director)

Co-investorsVivo Capital

BiotechNew York, US

Sergio Traversa(Executive Officer, Director)Eliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Casamento(Director)Paul Kelly(Director)Maged Shenouda(Director)

Co-investorsBioAdvanceBAM ElevateBraidwellCommodore CapitalOrbiMedRA Capital+2 more

BiotechSouth San Francisco, US

Grant E Pickering(Executive Officer, Director, Promoter)Ashish Khanna(Executive Officer)Jeff Fairman(Executive Officer)

BoardTracy Saxton(Director)William Newell(Director)Kurt von Emster(Director)in

Co-investorsAbingworthCTI Life Sciences Fund L.P.Foresite CapitalFrazier Life SciencesLongitude CapitalMedicxi+4 more

Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications.

BiotechHealthtechMedical DevicesAustin, US

Shanshan Xu(Founder & Chief Executive Officer)inHelmut Jeggle(Co-Founder)inThang Ho(Chief Development Officer)inCrystal MacKay(Chief Operating Officer)in

Co-investorsINCE CapitalRA CapitalBiotechnology Value FundREDMILESalvia

Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases.

BiotechHealthtech

Praveen Tipirneni(Chief Executive Officer)Liangsu Wang(Chief Scientific Officer)Zhong Liu(Chief Technology Officer)Aaron Pelta(Chief Business Officer)Colm White(Chief Program Officer)

Co-investorsAtlas VentureLAVvenBio Partners

Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases.

BiotechHealthtechMedical DevicesSuzhou, CN

William Wei Caoin

Co-investorsLAVLilly Asia VenturesOrbiMedExome Asset ManagementPivotal Life SciencesRA Capital+2 more

35Pharma is a biopharmaceutical company developing biologics to treat diseases with high unmet medical need.

BiotechHealthtech

Ilia(CEO)Maureen(CSO)

Co-investorsFrazier Life SciencesvenBio PartnersVivo Capital

AgelessRx offers prescription weight management medications delivered through a telehealth platform, including GLP-1 medications (semaglutide, tirzepatide), FDA-approved weight loss drugs (Wegovy, Zepbound), and supportive treatments like metformin and vitamin injections for adults seeking medically-supervised weight loss.

BiotechDigital HealthDirect to ConsumerHealthtechLongevityAnn Arbor, US

Anar Isman(Co-Founder & Chief Executive Officer)inRobert Michael Pejovich(Director of Finance of the Issuer)

Co-investors1/1 Capitalabrdn plcAngelini VenturesFidelity InvestmentsSanofi Ventures

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.

BiotechDigital HealthMedical DevicesVancouver, CA

François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)

Co-investorsAndreessen HorowitzDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude CapitalLumira Ventures+8 more

Apartment List operates an online rental marketplace that uses a quiz-based AI matching system to connect renters with apartments that fit their preferences and lifestyle.

AI & Machine LearningMarketplacesPropTechSan Francisco, US

John Douglas Kobs II(Executive Officer, Director)Charles Christopher Herndon(Executive Officer, Director)John Kobs(Founder)inChris Erickson(Co-founder)in

BoardJosh Hannah(Director)Dana Stalder(Director)in

Co-investorsAndre IguodalaAUTHENTIC VENTURESCanaan PartnersGlynn Capital ManagementMatrixTenaya Capital+3 more

Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.

BiotechDigital HealthMedical DevicesCambridge, US

DAVID ARTHUR SCOTT(Executive Officer)WINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)ANNIE HAZLEHURST(Director)

BoardKEITH CRANDELL(Director)DAVID R. WALT(Director)in

Co-investorsARCH Venture PartnersIllumina VenturesOno Venture Investment, Inc.TCG CrossoverAlly Bridge GroupSection 32+3 more

Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.

BiotechHealthtechMedical DevicesSan Francisco, US

Ivana Djuretic(Founder)inAndy Yeung(Founder)in

Co-investorsEmles Venture PartnersGoAhead VenturesMission Bay CapitalMission BiocapitalRA CapitalY Combinator+3 more

Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.

BiotechHealthtechSouth San Francisco, US

Jonathan Wall(Executive Officer)inSpencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)inBenson Fong(Executive Officer)Rahul Kakkar(Director)Greg Bell(Executive Officer)

Co-investorsAlpha Wave GlobalBioBritvenBio PartnersREDMILESamsara BioCapitalvenBio Global Strategic+1 more

Bigfoot Biomedical develops a diabetes management system that combines continuous glucose monitor data with a doctor's instructions to give insulin dose recommendations.

Digital HealthHealthtechMedical DevicesNew York, US

Jeffrey Brewer(Executive Officer, Director)Bryan Mazlish(Executive Officer, Director)Jon Brilliant(Executive Officer)

Co-investorsJDRF T1D FundWinklevoss CapitalXplorer CapitalSmile GroupVisionnaire Ventures, Llc

BiotechCambridge, US

Praveen Tipirneni(Executive Officer, Director)

BoardMichelle Doig(Director)inAaron Royston(Director)Michael Gladstone(Director)inXiaodi Su(Director)

Co-investorsAtlas VentureBain Capital Life SciencesLAVOmega FundsvenBio Global StrategicvenBio Partners+1 more

Calyxo develops medical devices for kidney stone removal, specifically a minimally invasive CVAC (Cavitation-Enabled Ablation and Clearance) system that has been FDA-cleared.

HealthtechMedical DevicesPleasanton, US

Chris Buchko(Executive Officer)inDouglas Hughes(Executive Officer, Director)Jee Shin(Executive Officer, Director)inMark Kidd(Executive Officer)Joe Catanese(Executive Officer, Director)

BoardRyan Drant(Director)in

Co-investorsQuesta CapitalAlly Bridge Group

Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.

BiotechSan Mateo, US

Gina Chapman(Executive Officer, Director)inAnup Radhakrishnan(Executive Officer)inCassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)

BoardAbraham Bassan(Director)

Co-investorsNextech InvestRed Tree VentureSamsara BioCapitalAlly Bridge GroupPerceptive Xontogeny VentureThird Rock Ventures

Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.

BiotechHealthtech

George Simeon(CEO)inGregory S. Curhan(CFO)Guy De La Rosa(CMO)in

Co-investorsAdjuvant CapitalOrbiMedRA CapitalSanofi VenturesHBM Healthcare InvestmentsMedicxi

Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders.

BiotechDeep TechDigital HealthMedical DevicesCardiff, GB

John Atack(Head of Biology & Founder)inSimon Ward(Chief Scientific Officer & Founder)in

Co-investorsAccess BiotechnologyCanaan PartnersSanofi VenturesSV Health InvestorsSR One Capital ManagementBritish Business Bank

The page presented is corporate content for Novartis, a pharmaceutical company that develops medicines across areas such as multiple sclerosis, cardiovascular disease, and oncology.

BiotechHealthtechSan Diego, US

Arthur T Suckow(Executive Officer)inArthur Suckow, Ph.D.(Founder)in

Co-investorsAccess BiotechnologyExSight VenturesRA Capital

Galvanize provides customized technical education and training programs to help enterprise teams build skills in AI, machine learning, XP and Agile practices, data pipelines, and cloud operations.

AI & Machine LearningEdTechEnterprise SoftwareFuture of WorkDenver, US

Christopher C. Onan(Executive Officer)James Deters(President and Chief Executive Officer)Lawrence Mandes(Managing Director, New Markets)in

BoardDaniel Pianko(Director)Tatiana Goldstein(Director)Jerrold Miller(Director)

Co-investorsSofinnova PartnersTeamworthy VenturesThe Colorado Impact FundVTF CapitalAlly Bridge GroupCatalyst Investors+5 more

Galvanize Therapeutics develops surgical ablation technology using its proprietary Aliya Pulsed Electric Field (PEF) energy to destroy soft tissue cells through regulated cell death mechanisms.

BiotechHealthtechMedical DevicesRedwood City, US

Doug Godshall(Executive Officer, Director)inSteve Anheier(Executive Officer)in

BoardJonathan Waldstreicher(Executive Officer)Antoine Papiernik(Director)inSeth Harrison(Director)Zack Scott(Director)

Co-investorsNorwest Venture PartnersAlly Bridge GroupATPFidelity InvestmentsGilmartin Capital LLCPerceptive Xontogeny Venture+2 more

IntelyCare operates a healthcare talent marketplace that connects nurses with care settings including hospitals, clinics, and other healthcare facilities.

B2B MarketplacesFuture of WorkHealthtechHR TechQuincy, US

Ike Nnah(Executive Officer, Director)inDavid Coppins(Executive Officer, Director)inPrince Nnah(Director)

Co-investorsEastward Capital PartnersEndeavour VisionEquitage Ventures, L.L.C.Generator VenturesKaiser Permanente VenturesLongitude Capital+3 more

Kardium develops the Globe Pulsed Field System, an all-in-one cardiac ablation catheter with 122 individually selectable electrodes that combines high-density mapping and pulsed field ablation.

BiotechHardwareHealthtechMedical DevicesBurnaby

Doug Goertzen(Executive Officer)inKevin Chaplin(Executive Officer, Director)in

BoardManuel Alba-Marquez(Director)Ian Ihnatowycz(Director)Armos Michelson(Director)David Rosa(Director)

Co-investorsGranada FundsEckuityFidelity InvestmentsQatar Investment Authority

BiotechSan Diego, US

Stephen W. Kaldor(Executive Officer, Director, Promoter)Eric Murphy(Executive Officer, Director)

BoardBret Zbar(Director)Carl Gordon(Director)Michael Rome(Director)

Co-investorsForesite CapitalNextech InvestRA CapitalVenrock Healthcare Capital PartnersViking Global Investors

Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.

BiotechHealthtechSouth San Francisco, US

Aetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)inKaren Flick(General Counsel)in

Co-investorsREDMILEVersant VenturesBAM ElevateFranklin TempletonHBM Healthcare InvestmentsInvus+4 more

Magnolia Medical develops diagnostic devices to reduce blood culture contamination and false-positive sepsis test results for hospitals and healthcare systems.

HardwareHealthtechMedical DevicesSeattle, US

Gregory J Bullington(Executive Officer, Director)Richard Patton(Co-founder)

BoardPaul Meister(Director)

Co-investorsEvidity Health CapitalLauder PartnersRhapsody Venture PartnersVivo CapitalHealthQuest CapitalRTW Investments L.P.+2 more

Parse.ly is a content analytics and audience intelligence platform offering a real-time dashboard, a content recommendation API, a data pipeline to warehouses, and AI-driven insights.

Data & InfrastructureMarketing TechMedia & Entertainment

Co-investorsHaatchHorizon Technology FinanceSahsen VenturesSARAS CAPITALSoleus Capital

BiotechFremont, US

Avanish Vellanki(Executive Officer)in

Co-investorsBiotechnology Value FundSamsara BioCapital

Restoring vision through optogenetics.

BiotechSan Francisco, US

Paul Bresge(Executive Officer, Director)Sean Ainsworth(Executive Officer, Director)

BoardTiba Aynechi(Director)inDmitry Kuzmin(Director)Raymond Camahort(Director)Hannah Chang(Director)

Co-investorsMRL Ventures Fund4BIO Capital4Bio VenturesDeerfield Management CompanyFranklin TempletonInvus+2 more

Star Therapeutics develops treatments aimed at addressing real-world patient needs.

BiotechSouth San Francisco, US

Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)Michelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)inGary Patou(Executive Officer)in

Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesSofinnova VenturesAgent Capital+8 more

Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.

BiotechHealthtech

K. Christopher Garcia(Founder)Susan Molineaux(CEO)inMartin Oft(Chief Scientific Officer)inNaiyer Rizvi(Chief Medical Officer)inGregory(Chief Technical Officer)Geoff(Chief Business Officer)

Co-investorsSamsara BioCapitalThe Column GroupBain Capital Life SciencesCanaan PartnersRA CapitalTCG Crossover+2 more

Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.

BiotechDigital HealthHealthtech

Vishal Patelin

Co-investorsAtlas VentureBorealis VenturesBorealis VenturesMagnetic VenturesOrbiMedAscenta Capital+3 more

Windward delivers AI-powered operational intelligence for maritime security and commercial applications, fusing behavioral analytics and multi-sensor data to detect threats and opportunities.

AI & Machine LearningData & InfrastructureDefense TechTel Aviv

Amiad Daniel(Executive Officer, Director)Matan Peled(Director)in

BoardDov Gatmon(Director)Patrick Poon(Director)Eden Shochat(Director)Thompson Hutton(Director)

Co-investorsAlephFTV CapitalThompson Hutton, LLCPivotal Life SciencesQiming Venture PartnersQuan Capital+3 more

Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases.

BiotechHealthtech

Co-investorsOrbiMedQuan CapitalRA CapitalSanofi VenturesSR One Capital ManagementNovo Holdings+3 more